ATORX 2,37 SEK (3,49 %) 02 Dec 2021 17:29 SV ABOUT ALLIGATOR RESEARCH & DEVELOPMENT CORPORATE GOVERNANCE INVESTORS NEWS CONTACT Tumor-directed immunotherapy of cancer Latest News 2 Dec 2021 – Alligator carries out a directed issue of shares to guarantors in connection with the completed rights issue 1 Dec 2021 – Alligator announces final outcome of rights issue 29 Nov 2021 – Alligator announces preliminary outcome of rights issue 12 Nov 2021 – Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021 More news Calendar 11 Feb 2022 ‐ Year End Report 2021 27 Apr 2022 ‐ Interim Report January-March 2022 5 May 2022 ‐ Annual General Meeting 2022 Preferential Rights Issue Q4 2021 Please follow this link for information on the preferential rights issue Q4 2021. Alligator Bioscience Q3 report Listen to the Webcast here About Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies. Links About Alligator Research and development Corporate governance Investors News Contact Privacy policy Contact Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden Phone: + 46 (0)46 540 82 00 info@alligatorbioscience.com ir@alligatorbioscience.com Subscribe Subscribe to get our pressreleases by email. SUBSCRIBE © Copyright 2018 - Alligator Bioscience AB

SV ABOUT ALLIGATOR RESEARCH & DEVELOPMENT CORPORATE GOVERNANCE INVESTORS NEWS CONTACT Start > Investors Share and shareholders Calendar Analysts IPO Financial reports Preferential rights issue Q1 2021 Preferential Rights Issue Q4 2021 Presentations Investors Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 8,000 shareholders. For further information, please contact: Julie Silber, Director IR and Communications julie.silber@alligatorbioscience.com Tel: 046-540 82 03 About Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies. Links About Alligator Research and development Corporate governance Investors News Contact Privacy policy Contact Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden Phone: + 46 (0)46 540 82 00 info@alligatorbioscience.com ir@alligatorbioscience.com Subscribe Subscribe to get our pressreleases by email. SUBSCRIBE © Copyright 2018 - Alligator Bioscience AB